Etrasimod meets mark in UC, first major readout since $6.7B Pfizer-Arena takeout

In the first of two Phase III readouts in ulcerative colitis for the keystone compound in Pfizer’s $6.7 billion takeout of Arena, S1PR1 modulator etrasimod significantly improved clinical remission rates, meeting the primary endpoint of the ELEVATE UC 12 study.

Pfizer Inc. (NYSE:PFE) reached a deal in December 2021 to acquire Arena Pharmaceuticals Inc., giving it etrasimod, a potential pipeline-in-a-product in development for Crohn’s disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The acquisition closed this month...